ICLR 6-K SEC Filing Analysis

Latest settled — T+5d

ICLR ▲ +5.19% at T+5d

SHORT call ✗ call lost -5.19% · α vs SPY -5.24% · entry $136.80 → $143.90

Next anchor: T+20d in 15d

Last close $152.24 (close Jun 8) · -11.29% from $136.80 entry (call sign-flipped)

Entry anchored
May 27, 03:59 PM ET
via Databento tick

T+1d

-0.53%

call +0.53% · α +0.78%

$136.07

settled 13d ago

T+5d

+5.19%

call -5.19% · α -5.24%

$143.90

settled 7d ago

T+20d

—

call — · α —

—

in 15d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

ICON plc filed Q4/FY2025 results alongside the conclusion of an Audit Committee investigation that found revenue overstatements of $65.3M (FY2023) and $92.7M (FY2024), leading to a restatement and disclosure of material weaknesses in internal controls. FY2025 GAAP diluted EPS fell 67.4% YoY to $2.90, adjusted diluted EPS fell 6.3% to $12.53, and adjusted EBITDA declined 8.4% to $1,530.7M; FY2026 guidance calls for revenue of $7,850-$8,150M and adjusted EPS of $10.00-$11.00, implying further contraction. The company also recorded a $364.2M goodwill impairment and a $101M impairment of non-financial assets, and revised its backlog methodology downward by $3.9B.

Actionable Insight

The restatement, material weaknesses, and downward revision to backlog methodology create significant uncertainty around ICON's reported financials and future revenue visibility. FY2026 guidance implies further adjusted EPS contraction, and the goodwill impairment signals structural issues in the Data Solutions unit. Monitor the May 28 conference call for details on remediation timeline and whether the Nasdaq deficiency notice (from the delayed 20-F) is resolved. The stock repurchase program provides a floor but does not offset fundamental headwinds.

Key Facts

FY2025 GAAP diluted EPS of $2.90 vs $8.90 in FY2024, a decline of 67.4%
FY2025 adjusted diluted EPS of $12.53 vs $13.37 in FY2024, a decline of 6.3%
FY2025 adjusted EBITDA of $1,530.7M vs $1,670.4M in FY2024, a decline of 8.4%
FY2025 revenue of $8,251.3M, up 0.8% YoY (0.1% constant currency)
Q4 2025 GAAP diluted EPS of $1.93 vs $3.58 in Q4 2024, a decline of 46.1%
Revenue restated downward by $65.3M for FY2023 (0.8%) and $92.7M for FY2024 (1.1%)
Material weaknesses in internal control over financial reporting identified
Goodwill impairment of $364.2M and impairment of non-financial assets of $101M recorded in FY2025
Backlog methodology revised, reducing reported backlog by $3.9B to $21.1B as of Oct 1, 2025
FY2026 guidance: revenue $7,850-$8,150M, adjusted diluted EPS $10.00-$11.00
$750M of stock repurchased in FY2025 at avg price of $167/share
Net debt of $2.8B with net debt to adjusted EBITDA ratio of 1.8x
Free cash flow of $862.0M for FY2025
Board additions: Kevin Egan (former PwC Ireland audit leader) and Jeff Elliott (former CFO of Exact Sciences)

Financial Impact

FY2025 GAAP net income fell to $229.3M from $739.1M in FY2024; adjusted net income fell to $989.8M from $1,110.2M. Revenue restated down by $158M cumulatively over FY2023-2024. FY2026 guidance midpoint of $8,000M revenue and $10.50 adjusted EPS implies continued year-over-year decline from FY2025 levels.

revenueepsnet incomeadjusted EBITDAgoodwillbacklog

Risk Factors

Failure to remediate material weaknesses could lead to continued restatement risk or SEC enforcement action
FY2026 guidance midpoint implies revenue decline from FY2025 actuals, suggesting organic contraction
Backlog methodology change reduces visibility into future revenue conversion
Nasdaq deficiency notice from delayed 20-F filing creates listing risk
Goodwill and asset impairments suggest potential further write-downs in Data Solutions

Market Snapshot

Exchange

Nasdaq

Sector

Services-Commercial Physical & Biological Research

Analyst Consensus

57% bullish (23 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
6-K Filing (Primary)	0001628280-26-038510
Document: iconplc6kq425.htm	0001628280-26-038510
Document: 0001628280-26-038510-index-headers.html	0001628280-26-038510
Document: 0001628280-26-038510-index.html	0001628280-26-038510
Document: 0001628280-26-038510.txt	0001628280-26-038510

3 reports for ICLR

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for ICLR — sortable, filterable
	Type				Now
May 27, 2026 13d ago	6-K BEARISH ★ 8/10	$136.80 $143.90	▼ −5.19%	▼ −5.24%	$152.24 (−11.29%)
May 27, 2026 13d ago	20-F BEARISH ★ 8/10	$136.80 $152.80	▼ −11.70%	▼ −11.38%	$152.24 (−11.29%)
May 26, 2026 14d ago	6-K BEARISH ★ 6/10	$118.45 $143.90	▼ −21.49%	▼ −21.02%	$152.24 (−28.53%)

US Market Status

Market Closed — Opens in 4h 8m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access